On May 21, 2025, the first China-Germany Anti-Cancer Summit concluded successfully. The summit was jointly organized by China Anti-Cancer Association (CACA) and World Association for Integrative Oncology (WAIO), attracting audiences from China, Germany, the UK, France, the Czech Republic, Switzerland, the Netherlands, Austria, Poland, and other countries. The global real-time online viewership reached 17.1 million. To date, the association has successfully held 19 international anti-cancer summits, with a cumulative viewership exceeding300 million.
The summit was chaired by Professor Wang Ying, Vice Chairman of CACA. The speakers featured authoritative experts in the field of oncology from both China and Germany, including: Prof. Fan Daiming, President of CACA, President of Asian Oncology Society (AOS), and President of the WAIO; Prof. Alexander Mundinger, Co-founder of the Breast Centre of Niels-Stensen Clinics, Osnabrueck and former President of the Senologic International Society (SIS); Prof. Jiang Yizhou, Vice President of Fudan University Shanghai Cancer Center and Board Member of the Youth Council of CACA; and Prof. Darius Dian, Medical Director and CEO of Gyn-munich GmbH, Professor of Gynecology and Obstetrics, LMU Munich.
At the opening ceremony, Vice President Wang Ying delivered a welcome speech. She emphasized the broad prospects and profound significance of cooperation between China and Germany in the field of cancer prevention and treatment, expressing her hope that experts from both countries would engage in thorough exchanges during the summit to jointly advance innovation in oncology.
◆Keynote Speeches: Cutting-Edge Exploration and Innovative Practices
◆ Prof. Fan Daiming: Development of Holistic Integrative Management of Cancer in China
Prof. Fan Daiming delivered a keynote speech titled "Development of Holistic Integrative Management of Cancer in China." He provided an in-depth analysis of the current status and challenges in China's cancer diagnosis and treatment, systematically elaborated on the innovative practices of China's integrated cancer care system, and introduced the "CACA Guidelines” for Holistic Integrative Management (HIM) of Cancer in detail.
Prof. Fan proposed the concept of "HIM"—encompassing prevention, screening, diagnosis, treatment, and rehabilitation —as well as the Chinese approach of "evaluation, support, control, care, and survival." He emphasized that integrated diagnosis and treatment represent a crucial direction in cancer therapy and that China's practices offer valuable experience for global peers in advancing cancer care.
◆Prof. Alexander Mundinger: Artificial Intelligence in Breast Cancer Diagnosis
Prof. Alexander Mundinger presented on the application of “Artificial Intelligence in Breast Cancer Diagnosis”. His lecture focused on the role of AI in breast cancer screening and diagnosis, discussing its advantages, limitations, and future trends.
He highlighted that AI can be effectively deployed in large-scale screening programs while also assisting in diagnostic techniques such as ultrasound, MRI, and PET. Breakthroughs in AI-driven breast cancer screening include analyzing breast density and lesion characteristics to predict cancer risk, enabling personalized screening intervals and improving detection rates among high-risk populations. Additionally, AI provides decision-making support for physicians, enhancing diagnostic accuracy and optimizing resource allocation
◆Prof. Jiang Yizhou: Breakthroughs in Precision Treatment for Triple-Negative Breast Cancer
In his report titled "Molecular Subtyping and Precision Treatment for Triple-Negative Breast Cancer (TNBC)", Prof. Jiang Yizhou emphasized that molecular subtyping-based individualized treatment strategies are pivotal in overcoming the therapeutic limitations of TNBC.
By identifying specific patient subtypes, clinicians can select targeted medications more effectively, significantly improving treatment outcomes while minimizing side effects. The introduction of the "subtype-based precision therapy" concept for TNBC has pioneered a new approach in the precision treatment of breast cancer, offering renewed hope for patients with this challenging disease.
◆Prof. Darius Dian: AI-Assisted Oncoplastic Surgery Planning
Prof. Darius Dian delivered a presentation titled "AI-Based Advice and Decision Support - Where Do We Stand in Planning Oncoplastic Surgery." He reviewed the evolution of breast cancer surgery and explored the application of AI in breast reconstruction, proposing image-based preoperative assessment and data-driven personalized treatment recommendations. Prof. Dian also emphasized the importance of addressing ethical and environmental concerns, such as data security and carbon footprints, while pursuing technological advancements.
◆Panel Discussion: Exploring the Future of AI in Cancer Prevention and Treatment
During the panel discussion, experts engaged in an in-depth dialogue on cutting-edge topics in oncology. Key themes included the application of AI across different cancer types, the critical role of data training, the impact of ethnic differences on AI models, the cost-effectiveness of molecular subtyping-guided precision therapy, and influence of environmental factors on cancer development. The panel unanimously agreed that AI holds vast potential in multiple cancer types, with data quality and diversity serving as the foundation for model training. Systematic training is essential to provide reliable diagnostic recommendations. This discussion laid important groundwork for future Sino-German collaboration in AI technology development, data sharing, and clinical translation.
◆Closing Outlook: Joint Efforts to Write a New Chapter in Cancer Care
This summit not only provided a platform for oncology experts from China and Germany to exchange ideas but also injected new momentum into the global fight against cancer. With the successful conclusion of the conference, collaboration between the two nations in cancer research and treatment will deepen further. Moving forward, both sides will work together to advance technological innovation and clinical practice, bringing renewed hope and brighter prospects to patients worldwide.
